# Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma

> **NCT07411144** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute, Egypt** · enrollment: 64 (actual)

## Conditions studied

- Diffuse Pleural Mesothelioma (DPM)

## Interventions

- **DRUG:** Gemcitabine (1000 mg/m2)

## Key facts

- **NCT ID:** NCT07411144
- **Lead sponsor:** National Cancer Institute, Egypt
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-15
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-03-15
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07411144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07411144, "Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07411144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*